Abstract: Systemic inflammation induces alterations in the finely tuned micromilieu of the brain that is continuously monitored by microglia. In the CNS, these changes include increased synthesis of the bioactive lipid lysophosphatidic acid (LPA), a ligand for the six members of the LPA receptor family (LPA1-6). Therefore, we studied the consequences of global LPA₅ knockout (−/−) on neuroinflammatory parameters in a mouse endotoxemia model and in primary microglia exposed to LPA in vitro. A single endotoxin injection (5 mg/kg body weight) resulted in lower circulating concentrations of TNFα and IL-1β and significantly reduced gene expression of IL-6 and CXCL2 in the brain of LPS-injected LPA₅−/− mice. LPA₅ deficiency improved sickness behavior and energy deficits produced by low-dose (1.4 mg LPS/kg body weight) chronic LPS treatment. LPA₅−/− microglia secreted lower concentrations of pro-inflammatory cytokine/chemokine responses to LPA and showed higher maximal mitochondrial respiration under basal and LPA-activated conditions, further accompanied by lower lactate release, decreased NADPH and GSH synthesis, and inhibited NO production. Collectively, our data suggest that LPA₅ promotes neuroinflammation by transmitting pro-inflammatory signals during endotoxemia through microglial activation induced by LPA.

Keywords: chemokines; cytokines; nitric oxide; endotoxin; immunometabolism; lysophospholipids

1. Introduction

Normal brain function depends on a balanced set of diverse lipid species, which have structural as well as signaling roles. Within the body, the brain has the second highest lipid content and diversity after adipose tissue [1]. High-resolution mass spectrometry-based lipidomic approaches revealed a distinct lipid signature of the brain that is substantially different from non-neural tissues, such as muscle and kidney [2]. Bioactive signaling lipids transmit their function by binding to specific receptors [3–5] and activating the downstream pathways [5,6]. In the periphery and the central nervous system (CNS), lysophosphatidic acid (LPA) species represent an important subclass of bioactive signaling lipids [6]. Signaling is determined by LPA receptor-triggered pathways in which six LPA receptors (LPA₁-6) couple to distinct classes of heterotrimeric G proteins, leading to a
variety of cellular activities [7,8]. In the CNS, the LPA/LPAR axis plays a pivotal role during neurodevelopment and homeostasis by modulating neurotransmission, synaptic plasticity, enzyme function, gene expression, and (neuro)inflammatory reactions [6].

Immune activation in the periphery affects the function of the CNS and is associated with an increased risk of developing neuropsychiatric and neurodegenerative diseases [9]. Microglia play an important role in this scenario since there is growing evidence that microglia activation and neuroinflammation can be induced by systemic inflammatory events [10,11]. This is ascribed to their ability to continuously monitor changes in the brain microenvironment through a specifically enriched set of surface receptors termed the “microglia sensome” [12]. Early studies had identified LPA receptor gene expression on rodent microglia [13], while recently validated mouse and human microglia RNAseq data sets define the microglia core sensome as a key set of 57 genes conserved between the mouse and human sensome [14] including LPA5 in mouse and human microglia (along with additional expression of LPA6 in humans) associated with the core sensome [14].

LPA5 [15] and LPA6 [16,17] are highly expressed in BV-2 cells and primary murine microglia [18,19], although LPA receptor expression in the brain is subject to developmental regulation [6,20] and depends on the genetic background of the animal model used [21]. LPA5 is considered to be a driving factor for acute and chronic ischemic injuries in the mouse transient middle cerebral artery occlusion (tMCAO) stroke model, and the LPA5 antagonist TCLPA5 has been shown to confer acute and long-term protection in this injury model [22,23]. These findings were ascribed to a pathogenic role of LPA5 closely associated with microglia activation in injured brains [22], likely via RAGE-dependent pathways [24]. Targeted deletion of LPA5 identified a novel role for this receptor in mechanically or chemically induced murine neuropathic pain models [25,26]. Consistently, the LPA5 inhibitor AS2717638 ameliorated mechanical allodynia and thermal hyperalgesia in rodent models of neuropathic pain [27]. In microglia, LPA5 induces a polarization program toward a neurotoxic phenotype, since genetic (siRNA) [22] and pharmacological (TCLPA5, Cpd3, AS2717638) approaches revealed that inhibition of this receptor attenuates the neuroinflammatory output of the cells [28,29].

LPA signaling plays an important role in microglia polarization [18,30], the neuroinflammatory response [31], and a shift in cellular metabolic pathways [32,33]. To monitor the role of LPA5 in endotoxemia in the absence of pharmacological antagonists (and potentially associated off-target effects), we used a global LPA5 knockout mouse model. Using this mouse model, we studied the peripheral and central inflammatory response in an endotoxemia model utilizing wildtype (wt) and LPA5-deficient (−/−) mice. In vitro, we investigated the impact of LPA on cyto-/chemokine secretion and basic immunometabolic parameters (mitochondrial function, lactate, NADPH, GSH, and nitric oxide synthesis) in microglia isolated from newborn wt and LPA5−/− mice.

2. Materials and Methods

2.1. Animals

Mice were housed and bred in a clean environment and a 12 h/12 h light–dark cycle with chow diet and water access ad libitum. All animal experiments were approved by the Austrian Federal Ministry of Education, Science and Research (BMWF-66.010/0067-V/3b/2018 and 2020_0.547.884). All measures were taken to minimize animal suffering and distress.

The genotyping protocols for LPA5−/− genetically modified mice have been described previously [25]. Briefly, homozygous LPA5-null mutant mice were generated by targeted deletion of the LPA5 gene to eliminate and replace most of the LPA5 coding region in C57BL/6j mice. Heterozygous mice were mated to each other to obtain wildtype (wt; +/+ ) and null mutant offspring (−/−). Genotypes were confirmed by PCR genotyping using the following primers:

GFP Int Rev, 5-GTGGTGCAGATGAACCTTCAAG-3;
92GTFor, 5-CAGAGTCTGTATCGCCACCAG-3; and
Male wt and LPA5−/− mice aged 12–16 weeks weighing 20–30 g were injected i.p. with PBS or LPS (5 mg/kg body weight in PBS). Twenty-four hours post injection, the animals were euthanized, perfused, and brains were collected in QIAzol Lysis Reagent (Qiagen, Hilden, Germany) for RNA isolation.

Blood (200–300 µL) was isolated by cardiac puncture. The tubes containing the blood samples were kept at room temperature for 1 h and then centrifuged at 5000×g for 10 min. The clear supernatant (serum) was collected, diluted 1:10 and used for ELISA analyses.

2.2. Indirect Calorimetry (Metabolic Cage Monitoring)
LPA5−/− and wt mice were individually housed in PhenoMaster cages (TSE Systems, Bad Homburg, Germany). We determined energy intake and expenditure as well as ambulatory movements in the mice over 5 days before and for 4 days during chronic LPS i.p. application (1.4 mg/kg body weight in PBS every 24 h). We chose this chronic low-dose regimen to observe animal behavior over an extended period of time, which is not possible in the acute high-dose LPS model (5 mg/kg body weight) since animal suffering increases at time points > 1 d post LPS application [34]. A comparable chronic treatment regimen (four daily LPS injections of 1 mg/kg) was shown to induce global microglia activation in C57BL/6 mice [35]. Oxygen consumption (VO2) and carbon dioxide production (VCO2) were simultaneously measured every 15 min by indirect gas calorimetry.

Since food consumption from the built-in food containers (which are localized above the light beams that monitor locomotion) may be too challenging for some animals after the LPS injections, we decided to place food pellets directly in the cage and measure food consumption manually. During the adaption phase, cumulative food consumption was divided by the days of the adaption phase to measure average food consumption. During the LPS treatment, food consumption was measured manually every day just before the LPS injection.

2.3. RT-qPCR Analysis
We isolated total RNA from the brain with the RNeasy Lipid Tissue Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol. Total RNA was quantitated using NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA) and reverse-transcribed using the SuperScript® III reverse transcription kit (Invitrogen, Waltham, MA, USA). Quantitative real-time PCR (qPCR) using the QuantifastTM SYBR® Green PCR kit (QIAGEN, Hilden, Germany) was performed on the Applied Biosystems 7900HT fast real-time PCR system. Gene expression was normalized to the expression of hypoxanthineguanine phosphoribosyltransferase (HPRT) as housekeeping gene. Expression profiles and associated statistical parameters were calculated using the 2−ΔΔCT method. Primer sequences are listed in Table 1.

2.4. Primary Microglia Cultures
To isolate primary murine microglia from the cortices of newborn (P0–P4) wt and LPA5−/− mice, we dissected brain cortices from the entire brain, and the meninges were removed and cut into small pieces with scissors. Tissues were trypsinized (0.1% trypsin, 25 min, 37 °C, 5% CO2), and centrifuged at 1700 rpm for 7 min. The supernatant was aspirated and the pellet was suspended in DMEM. This cell suspension was cultured in poly-D-lysine (PDL; 5 µg/mL)-coated 75 cm2 tissue culture flasks (4 brains per flask) in DMEM supplemented with 15% FCS, 1% penicillin, 1% streptomycin, and 1% L-glutamine. After cultivation of the cells for another 10 to 14 days, we removed microglia from the mixed glia cell cultures by vigorously tapping the culture flasks on the bench top. Microglia were then seeded onto PDL-coated cell culture plates for further use.
Table 1. Primers used for qPCR experiments during the present study.

| Gene    | Company | Catalogue Number | Forward/Reverse Primers |
|---------|---------|------------------|-------------------------|
| iNOS    | Qiagen  | QT00100275       |                         |
| HPRT    | Qiagen  | QT00166768       |                         |
| Arg-1   | Invitrogen |             | F: TGGCTTGCCGAGACGATGAC  |
|         |          |                 | R: GCTCAGGTAATCGGCTTTTT  |
| TNFα    | Invitrogen |             | F: ACTTCGGGGTGATCGGTCC   |
|         |          |                 | R: GGCTACAGCTGTTCACTCG   |
| IL6     | Invitrogen |             | F: CTCTCCACCTCAATGGAGAG  |
|         |          |                 | R: TGATGCTTGGGTCTCCTTGT  |
| IL1β    | Invitrogen |             | F: CTCTCCACCTCAATGGAGAG  |
|         |          |                 | R: CGGTGCTTGGGTCTCCTTGT  |
| CXCL10  | Invitrogen |             | F: TTCTGCTCTCATCTGCTG    |
|         |          |                 | R: AGACATCTCTGCTCATCTCC  |
| CXCL2   | Invitrogen |             | F: AGTCGAAATGCGGTGCAATG  |
|         |          |                 | R: GCCCTGAGTGGCTGATGA     |
| CCL5    | Invitrogen |             | F: GCTGCTTGGTTACCTCTCC   |
|         |          |                 | R: TCGAGTGAACAAACGACTGC  |

2.5. LPA Treatment

The aqueous LPA (1-Oleyl-2-hydroxy-sn-glycero-3-phosphate; Sigma-Aldrich, St. Louis, MO, USA; Cat. L7260) stock solution (5 mM) was aliquoted and stored at −70 °C. Fresh aliquots were used for the experiments. Primary microglia were plated out in 12- or 24-well plates and allowed to adhere for 2 days. Before treatments, cells were incubated in serum-free DMEM overnight. The following day, fresh, serum-free medium was added, followed by the addition of LPA.

2.6. Seahorse XF Analyzer Respiratory Assay

Cells (6 × 10^4 cells per well) were seeded in Seahorse XFe96 FluxPaks for metabolic analysis with an extracellular flux analyzer XF96 (Seahorse, Agilent, Santa Clara, CA, USA). The sensor cartridge was hydrated in a 37 °C non-CO₂ incubator one day before the experiment. Cells were serum-starved overnight, treated with LPA at the indicated concentrations for the given time periods, washed, and incubated with the appropriate assay medium for 1 h in a 37 °C non-CO₂ incubator according to the manufacturer’s instructions. Cellular oxygen consumption rate (OCR) was determined using the XF Cell Mito Stress Test (Agilent). Optimized stressor concentrations were added as follows: 2 µM oligomycin (complex V inhibitor), 1.75 µM cyanide p-trifluoromethoxy-phenylhydrazone (FCCP; proton gradient disruption), and 2.5 µM antimycin A (inhibitor of complex I and III). OCR was normalized to protein concentrations, and data from 3 independent experiments are shown.

2.7. ELISA

Primary cells (5 × 10^5 per well) were seeded onto 6-well plates, serum-starved overnight, and then treated with LPA for the indicated time periods. Thereafter, the supernatant was collected and stored at −80 °C until further use. Murine ELISA development kits (Peprotech, Cranbury, NJ, USA) were used to determine concentrations of cytokines (IL-1β, TNFα, IL-6) and chemokines (CCL5 (RANTES), CXCL2 (MIP-2), and CXCL10 (IP-10)) using external standard curves.

2.8. Lactate Measurement

Lactate content in the supernatant was measured using the EnzyChrom™ Glycolysis Assay Kit (ENZO Life Sciences, Lausen, Switzerland) according to the manufacturer’s protocol. Briefly, primary microglia (96-well plate, 6 × 10^4 cells per well) were allowed to adhere, then incubated in serum-free medium and treated with LPA for indicated time...
periods. At the end of the treatment, the supernatant was collected and treated with the enzyme mix under brief shaking. Optical density was measured at 565 nm to quantify the lactate content.

2.9. NADPH/NADP Assay

Nicotinamide nucleotides were assayed using the NADP/NADPH assay kit (Abcam, Cambridge, UK) according to the manufacturer’s instructions. Primary microglia were seeded onto PDL-coated 12-well plates at a density of $5 \times 10^5$ per well and serum-starved overnight prior to the experiments. Cells were treated with the given concentrations of LPA for the indicated time periods, after which the medium was removed, cells were washed twice with ice-cold PBS, and NADP/NADPH were extracted with the extraction buffer. The samples were deproteinized using 10 kDa Spin Columns (Abcam, Cambridge, UK) before performing the assay. An aliquot of the sample was used to measure total NADP (NADP and NADPH). Another part of the sample was heated at 60 °C for 30 min to decompose NADP for NADPH measurement. Ten µL of the sample were mixed with NADP cycling mix to convert NADP to NADPH. Thereafter, 10 µL of NADPH developer were added into each well, mixed, and incubated at room temperature for 1–4 h. Multiple readings were taken at OD 450 nm. The ratio of NADPH/NADP was calculated as follows: NADPH/NADP ratio = NADPH/(NADPt − NADPH).

2.10. Glutathione Assay

Primary microglia (5 × 10^4 per well) were seeded overnight in clear-bottom black 96-well plates to allow cells to adhere, incubated in serum-free medium, and treated with LPA (1 or 5 µM) for the indicated time periods. To measure intracellular glutathione content, cells were incubated with the GSH-Glo™ reagent (GSH-Glo™ Glutathione Assay Kit; Promega Corporation, Madison, WI, USA) for 30 min. After addition of the luciferin detection reagent, luminescence was measured to quantify the glutathione content according to the manufacturer’s protocol.

2.11. Determination of Nitric Oxide (NO)

Total nitrate content was measured in the supernatant of cells incubated with the indicated compounds in serum-free medium using the total nitric oxide assay kit (ENZO Life Sciences, Lausen, Switzerland) according to the manufacturer’s protocol. This assay detects a colored azo-dye product after the enzymatic conversion of nitrate to nitrite by nitrate reductase, followed by the Griess reaction. Nitrite concentrations in the samples were calculated by a standard curve in the range of 0–100 µM using nitrate as standard.

2.12. Statistical Analysis

Data are presented as mean ± SEM of at least 3 independent experiments (performed in triplicate), unless otherwise stated. Statistical analyses were performed using GraphPad Prism6 software. Significance was determined by unpaired Student’s t-test (two groups) or two-way ANOVA followed by Bonferroni correction (>two groups). Values of $p < 0.05$ were considered significant.

3. Results

3.1. Endotoxemia Is Reduced in LPA₅⁻/⁻ Mice

In vivo, we investigated a potentially protective role of global LPA₅ deficiency in an LPS-induced endotoxemia mouse model. Adopting a previously published protocol [36], wt and LPA₅⁻/⁻ mice were injected i.p. with LPS (5 mg/kg body weight) and sacrificed 24 h later. Cyto-/chemokine concentrations and gene expression were determined in serum and in brain homogenates, respectively. Serum ELISA measurements revealed that LPS administration significantly increased TNFα, IL6, and IL-1β concentrations (Figure 1A–C). In LPA₅⁻/⁻ mice, this increase was significantly lower for TNFα and IL-1β, while IL-6 concentrations remained unaffected (Figure 1A–C).
3. Results

3.1. Endotoxemia Is Reduced in LPA5-/- Mice

In vivo, we investigated the effects of LPA5 deletion on TNFα, IL-6, and IL-1β expression levels, as well as cyto- and chemokine secretion, locomotor activity, and RER in PBS-injected animals (Figure 2A–F). iNOS (M1 marker) and Arg-1 (M2 marker) were partially recovered from LPS-induced sickness behavior (despite the consecutive injection).

Following brain RNA isolation, gene expression of TNFα, IL-6, IL-1β, CXCL10, CXCL2, CCL5, iNOS, and Arg1 was analyzed by qPCR. In both genotypes, cyto- and chemokine expression levels were significantly enhanced in response to LPS when compared to vehicle (PBS)-injected animals (Figure 2A–F). iNOS (M1 marker) and Arg-1 (M2 marker) were upregulated in response to LPS; however, in wt animals, this effect was statistically not significant (Figure 2G,H). In LPA5-/- mice, the increase of cyto- and chemokine mRNA expression was consistently lower as compared to wt (Figure 2A–F). These observations reached statistical significance for IL-6 and CXCL2.

3.2. Improved Metabolic Performance of LPA5+/+ Mice after Short-Term, Low-Dose LPS Treatment

To monitor potential differences in animal behavior and energy expenditure, wt and LPA5+/+ mice were housed in metabolic cages and subjected to a low-dose, chronic LPS regimen (1.4 mg LPS/kg body weight every 24 h for 4 d). During the preceding 5 d adaptation phase, wt or LPA5+/+ mice with ad libitum access to food and water were individually kept in metabolic cages. Under these basal conditions, feeding behavior, locomotion during the night cycle, respiratory exchange ratio (RER) and energy expenditure (EE) during the night cycle of wt mice were not significantly different from LPA5+/+ animals (Figure S1A–H). Locomotion and energy expenditure during the day cycle was slightly lower (p < 0.05) for LPA5+/+ mice (Figure S1D,H).

In comparison to basal conditions, animals of both genotypes exhibited classical signs of sickness behavior 24 h after the first LPS application (Figure 3). This is reflected by decreased water and food intake (Figure 3A,B), locomotion (Figure 3C,D), RER (Figure 3E,F) and EE (Figure 3G,H). However, in contrast to wt mice, several parameters of sickness behavior were significantly less pronounced in LPA5+/+ animals during the early acute inflammatory phase 24 h after the first LPS dose. This was reflected by higher water (night cycle) and food consumption, locomotor activity, as well as RER (night cycle) in comparison to LPS-injected wt animals (Figure 3A,B,D,F). The corresponding data for the entire 96 h monitoring period are shown in Figure S2 and indicate that the animals partially recovered from LPS-induced sickness behavior (despite the consecutive injection). Most of the metabolic parameters (except total food intake and RER during the night cycle; Figure S2A,F) were comparable between wt and LPA5+/+ mice.

3.3. LPA5 Regulates LPA-Induced Secretion of Cyto-/Chemokines in Primary Microglia

In response to acute or chronic endotoxemia, LPA levels and gene expression of autotaxin (ATX) and several LPA receptors (including LPA5) are upregulated in mouse brain homogenates [31]. Since LPA provides an induction signal for the transition of microglia toward a pro-inflammatory phenotype, we tested the hypothesis that LPA5 deficiency might affect this phenotypic switch. Indeed, analysis of cyto-/chemokine secretion in wt and LPA5+/+ microglia revealed remarkable differences between the two genotypes. LPA
increased the concentrations of TNFα, IL-6, and IL-1β (Figure 4A–C) and the chemokines CXCL10, CXCL2, and CCL5 (Figure 4D–F) at one or more time points in wt microglia. In LPA5−/− cells, this pro-inflammatory response was attenuated, with significantly reduced secretion of TNFα and IL-6 (Figure 4A,B). LPA-induced effects on IL-1β (Figure 4C) and chemokine secretion (Figure 4D–F) were virtually absent in LPA5−/− cells.

Figure 2. LPA5 deletion attenuates expression of pro-inflammatory genes in mouse brain. Wt and LPA5−/− mice were injected i.p. with PBS (n = 4) or LPS (5 mg/kg; n = 6). After 24 h, the animals were sacrificed and perfused. Brains were processed for RNA isolation and gene expression of (A) TNFα, (B) IL-6, (C) IL-1β, (D) CXCL10, (E) CXCL2, (F) CCL5, (G) iNOS, and (H) Arg-1 was evaluated by qPCR. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as housekeeping gene. Expression was calculated using the 2−ΔΔCt method. Results are presented as mean values ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 compared to wt PBS control; & p < 0.05, && p < 0.01 compared to LPA5−/− PBS control; # p < 0.05 compared to LPS-treated wt mice; two-way ANOVA with Bonferroni correction).
Figure 3. Improved metabolic performance of LPA<sup>5-/-</sup> mice after initial LPS treatment. Short-term metabolic cage readouts 24 h after the first LPS injection are shown. Wt and LPA<sup>5-/-</sup> mice were housed at room temperature in metabolic cages with free access to chow diet and water. Mice were injected daily with LPS (i.p., 1.4 mg/kg body weight) for 4 d. (A) water consumption, (B) food intake, (C) real-time locomotor activity, (D) mean locomotor activity, (E) real-time measurement of respiratory exchange ratio (RER), (F) mean RER, (G) real-time energy expenditure (EE) measurement, and (H) mean EE. (Data represent as mean values ± SEM for wt (<i>n</i> = 6) and LPA<sup>5-/-</sup> (<i>n</i> = 5) mice. Significance was calculated by Student’s t-test. * <i>p</i> < 0.05, **, <i>p</i> < 0.01, *** <i>p</i> < 0.001 compared to LPS-treated wt mice.
3.3. LPA5 Regulates LPA-Induced Secretion of Cyto-/Chemokines in Primary Microglia

In response to acute or chronic endotoxemia, LPA levels and gene expression of autotaxin (ATX) and several LPA receptors (including LPA5) are upregulated in mouse brain homogenates [31]. Since LPA provides an induction signal for the transition of microglia toward a pro-inflammatory phenotype, we tested the hypothesis that LPA 5 deficiency might affect this phenotypic switch. Indeed, analysis of cyto-/chemokine secretion in wt and LPA5-/- microglia revealed remarkable differences between the two genotypes. LPA increased the concentrations of TNF\(\alpha\), IL-6, and IL-1\(\beta\) (Figure 4A–C) and the chemokines CXCL10, CXCL2, and CCL5 (Figure 4D–F) at one or more time points in wt microglia. In LPA5-/- cells, this pro-inflammatory response was attenuated, with significantly reduced secretion of TNF\(\alpha\) and IL-6 (Figure 4A,B). LPA-induced effects on IL-1\(\beta\) (Figure 4C) and chemokine secretion (Figure 4D–F) were virtually absent in LPA5-/- cells.

**Figure 4.** LPA5 regulates LPA-induced secretion of cyto-/chemokines in primary microglia. Wt and LPA5-/- cells were treated in the absence (C) or presence of LPA (1 \(\mu\)M) for the indicated times. Supernatants were collected and (A–C) cytokine (TNF\(\alpha\), IL-6, and IL-1\(\beta\)) and (D–F) chemokine (CXCL10, CXCL2, and CCL5) concentrations were quantified by ELISA. Values are expressed as mean ± SEM of five independent experiments. * \(p < 0.05\), ** \(p < 0.01\) compared to wt control; # \(p < 0.05\), ## \(p < 0.01\) for LPA5-/- compared to wt cells (two-way ANOVA with Bonferroni correction).

To account for potential effects mediated by other LPA receptors (in particular LPA6 that is highly expressed by primary microglia [18]) or potential LPA loss during sample preparation [37], all in vitro experiments were performed also with 5 \(\mu\)M LPA. The higher LPA concentration was chosen to account for the lower LPA affinity of LPA6 [17]. Similar results for cyto-/chemokine secretion were obtained in response to 5 \(\mu\)M (Supplementary Figure S3).

3.4. LPA5-/- Microglia Have Higher Mitochondrial Capacity as Compared to wt Cells

Microglia, like peripheral immune cells, are able to utilize different energy metabolites to immediately adapt to chemical alterations in the local microenvironment [38]. Earlier studies from our group have indicated that LPA alters the metabolic profile of the mouse BV-2 microglia cell line to a glycolytic phenotype via an AKT/mTOR/HIF1\(\alpha\)-dependent pathway [32] and drives them toward a pro-inflammatory phenotype via LPA5 [29,36]. To gain insight into whether the core sensome member LPA5 contributes to metabolic plasticity in microglia, we monitored basic metabolic parameters and inflammatory output in response to LPA in wt and LPA5-/- cells.

In the first set of experiments, we examined mitochondrial function in real time using the Seahorse XF Cell Mito Stress Test. During Seahorse flux analysis, we compared mitochondrial function between wt and LPA5-/- cells under basal (PBS) and LPA-activated...
conditions and assessed changes in the oxygen consumption rate (OCR) after treatment with an ATP synthase inhibitor (oligomycin), H+ ionophore (FCCP), and under electron-transport chain inhibition (rotenone and antimycin A). These experiments revealed that, under basal conditions, LPA5-/− microglia showed higher OCR after 2 and 24 h in comparison to wt cells (Figure 5A,B). In response to LPA (1 µM, 2 h), maximal respiration (Figure 5E) was significantly higher in LPA5-/− microglia as compared to wt cells, whereas basal respiration (Figure 5C), ATP production (Figure 5D), and spare respiratory capacity (Figure 5F) showed an upward trend. The increase in the latter two parameters was sustained up to 24 h in LPA5-/− cells (Figure 5E,F). Qualitatively and quantitatively comparable observations were made during Seahorse analysis of primary cells cultured in the presence of 5 µM LPA (Figure S4).

Figure 5. LPA5 regulates mitochondrial respiration in primary microglia. (A,B) Oxygen consumption rate (OCR) in the absence and presence of LPA (1 µM) for 2 or 24 h was measured using the XF Cell Mito Stress Test. Primary microglia isolated from wt and LPA5-/- mice were treated with 2 µM oligomycin, 1.75 µM FCCP, and 2.5 µM antimycin A in XF assay medium to assess mitochondrial function parameters. Bar graphs show (C) basal mitochondrial respiration, (D) maximal mitochondrial respiration, (E) ATP linked respiration, and (F) spare respiratory capacity. Values are expressed as mean ± SEM of three independent experiments. ##p < 0.01, ###p < 0.001 LPA5-/- compared to wt cells; two-way ANOVA with Bonferroni correction.

3.5. LPA5 Deletion Attenuates LPA-Induced Lactate, NADPH, GSH, and NO Synthesis

In response to pro-inflammatory stimuli, metabolism of microglia shifts from OXPHOS to aerobic glycolysis [39]. To investigate potential differences in metabolic rewiring in LPA-polarized wt and LPA5-/− cells, we quantified the levels of extracellular lactate, the
major end product of aerobic glycolysis. These analyses revealed that lactate secretion by wt microglia was significantly increased by LPA (0.07 vs. 0.23 and 0.38 vs. 0.52 mM; control vs. LPA at 2 h and 24 h, respectively; Figure 6A). In LPA5−/− cells, this rise in LPA-induced lactate secretion was virtually absent, indicating an important role for LPA5 during maintenance of metabolic plasticity.

To get an indication about the cellular redox status of LPA-treated wt and LPA5−/− microglia, we analyzed the intracellular NADPH/NADP ratio, reduced glutathione (GSH) content, and nitric oxide (NO) release. The rationale for these analyses is based on earlier observations from our group [32], in which we showed that LPA treatment of BV-2 cells induces phosphorylation of nuclear factor erythroid 2-related factor 2 (Nrf2). Activation of the Nrf2 pathway transcriptionally regulates several key enzymes involved in the antioxidant response, including glucose-6-phosphate dehydrogenase (G6PD) and glutamate cysteine ligase subunits that catalyze the first step of GSH synthesis. Activation of G6PD activates the pentose phosphate cycle, which (in the oxidative branch) generates NADPH as an indispensable co-factor for NO synthesis via inducible NO synthase (iNOS). The NADPH/NADP ratio in wt cells was increased by 5-fold in response to a 24 h LPA exposure, whereas this response was significantly attenuated in LPA5−/− cells (Figure 6B). In response to LPA, wt microglia time-dependently increased their intracellular GSH content. In contrast, under basal conditions, the GSH content was slightly lower (statistically not significant) in LPA5−/− cells, whereas the LPA response of intracellular GSH levels was almost absent at all time points investigated (Figure 6C). As previously reported [40], LPA treatment increased NO concentrations in the cellular supernatant leading to a 2.8-fold increase after 24 h. This response was not observed in LPA5−/− cells (Figure 6D). Comparable results were obtained with cells exposed to 5 µM LPA (Figure S5).

Figure 6. LPA5 regulates extracellular lactate content, NADPH/NADP ratio, glutathione concentration, and NO production in primary microglia. Wt and LPA5−/− cells were cultivated in serum-free medium in the absence or presence of LPA (1 µM). (A) Lactate content was measured by EnzyChrom™ Glycolysis Assay Kit. (B) NADPH/NADP ratio was measured using the NADP/NADPH assay kit (Abcam). (C) Glutathione (GSH) concentration was quantified with the GSH-Glo Assay kit. (D) The production of NO was determined by measuring the total nitrate concentration in the supernatants. Results are presented as mean values ± SEM of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to wt controls, # p < 0.05, ## p < 0.01, ### p < 0.001 for LPA5−/− compared to wt cells, two-way ANOVA with Bonferroni correction.
4. Discussion

Although it is not entirely clear under which conditions peripheral LPS crosses the blood–brain barrier (BBB) to trigger neuronal damage [41,42], there is a consensus that peripherally induced endotoxemia has the potential to cause neuroinflammation in experimental animal models and the human organism [43]. This results in microglia and astrocyte activation, memory loss, as well as destruction of synapses and apoptosis of neurons [44]. We have previously demonstrated that pharmacological interference with the ATX/LPA/LPA$_5$ axis attenuates LPS-induced neuroinflammation in vivo and in a microglia cell line in vitro [36]. Here, we confirm and extend these findings to LPA$_5^{-/-}$ mice and primary LPA$_5^{-/-}$ microglia, thereby eliminating concerns regarding potential off-target effects of synthetic LPA$_5$ antagonists. In particular, this global knockout model enabled us to directly demonstrate the involvement of LPA$_5$ during the LPS-mediated peripheral and central inflammatory response, and a certain (short-term) contribution to energy expenditure and sickness behavior. In addition, the pro-inflammatory response of microglia towards LPA was less pronounced in LPA$_5^{-/-}$ microglia, a fact that might be partially attributed to the different immunometabolic phenotype induced in the knockout cells. A question arising from the present study is clinical translatability. As a lipid-activated receptor belonging to the GPCR family, LPA$_5$ (among the other members of the receptor family) clearly qualifies as a druggable target in the CNS [45]. GPCRs are of high interest as pharmacological targets, since they are involved in pathophysiology, and druggable sites within this receptor class are accessible at the extracellular leaflet. Consequently, approximately 35% of FDA-approved drugs act on GPCRs [46]. Although drug delivery to the brain is restricted by the BBB [47], the situation for the LPA5 antagonist AS2717638 is encouraging since it accumulates in rat brain and displays neuroprotective action [27]. However, considering known differences between mouse and human immunology, findings in murine models must not necessarily reproduce in the human system [48].

Although Banks and Robinson have reported minimal BBB penetration of i.v.-injected $^{125}$I-LPS [41], Vargas-Caraveo suggested that LPS may be transported across the BBB via a lipoprotein-mediated pathway [42]. There is also evidence that LPS associates with Aβ$_{1-40/42}$ within amyloid plaques and around vessels in brains of patients suffering from Alzheimer’s disease [49]. In addition, i.p. application of LPS provokes several features of sepsis and potentiates peripheral synthesis of cytokines and chemokines. Among these, TNF$\alpha$ has been shown to induce neuroinflammation via the TNF receptor 1 signaling pathway [50]. Additionally, this LPS transcytosis-independent pathway causes elevated gene expression of iNOS and TNF$\alpha$ in the brain [50], in accordance with data obtained in the present study (Figures 1 and 2). Thus, reduced peripheral TNF$\alpha$ synthesis (Figure 1) would be expected to attenuate the neuroinflammatory response. Rat and human brain microvascular endothelial cells express TLR2, TLR3, TLR4, and TLR6 [51]. LPS interaction with TLR4 on these essentially non-immune cells initiates an inflammatory response by inducing IL-1$\beta$, IL-18, IL-6, and TNF$\alpha$ production [52]. In response to peripheral LPS, LPA concentrations in mouse brain and serum increase significantly and could amplify the inflammatory response [31]. Of note, LPA stimulates CD14 transcription and translation [53] and could, via activation of this TLR4-associated coreceptor, enhance the LPS-mediated inflammatory response. Thus, multiple pathways initiated at the periphery may converge at the BBB, leading to an inflammatory microglia phenotype in the CNS in response to peripheral LPS.

Microglia play a central role in the initiation of neuroinflammation by surveying the chemical composition of the environment. Of relevance for the present study, LPA$_5$ was identified as a core sensome member in mouse and human microglia [14]. As an extracellular, ligand-activated receptor almost exclusively expressed by microglia/macrophages (https://www.brainrnaseq.org/ (accessed on 7 February 2022); [54]), it is located in a strategic position to detect pathological alterations in the extracellular milieu and convey information to induce a phenotypic transition of microglia. Consequently, LPA$_5$ was shown to play a disease-amplifying role in stroke [22,23,55], neuropathic pain [25,27,56], itching...
sensation [57], neuroinflammation [36], and during microglia polarization toward a neurotoxic phenotype [29,36]. Our group has previously shown that pharmacological antagonism of ATX (PF8380) and LPA₅ (AS2717638) downregulated gene and protein expression of several pro-inflammatory markers in brains of LPS-injected C57BL/6 mice [36]. In line with this, results of the present study demonstrated reduced cyto-/chemokine gene expression in brains of LPS-injected LPA₅⁻⁻ mice (Figure 2), thereby replicating findings obtained with the LPA₅ antagonist AS2717638. These data validate and re-confirm an important role of this lipid-activated receptor during induction of neuroinflammatory symptoms. Whether these observations are due to downregulation of TLR4 expression and subsequent attenuation of the inflammatory response (as observed with AS2717638; [36]) was not experimentally addressed in the present study.

In vivo energy metabolism was comparable between wt and LPA₅⁻⁻ mice under basal conditions (Figure S1). In the endotoxemia model, global LPA₅ deficiency provided protection against LPS-induced sickness behavior, lethargy, and energy deficits within the first 24 h of treatment (Figure 3). This protective effect was, however, lost within the following 72 h of this low-dose LPS treatment regimen (Figure S2). Our short-term observations in LPA₅⁻⁻ mice might be due to lower peripheral TNFα or IL-1β (but unchanged IL-6) synthesis (Figure 1), both of these cytokines resembling classical inducers of sickness behavior in mice and humans [58]. Whether or not the partial recovery in response to repeated LPS injections is due to the development of endotoxin tolerance [59] is currently unclear. Of note, repeated injections of LPS trigger epigenetic modifications of microglia that result in activation of the mTOR/HIF-1α axis [60] and consequently lead to increased (aerobic) glycolysis [61], comparable to LPA-stimulated microglia observed in a previous [32] and in the present study (Figure 6).

In vitro, LPA-stimulated LPA₅⁻⁻ microglia showed reduced cyto-/chemokine synthesis, better mitochondrial fitness, and altered metabolic properties compared to wt cells, independent of whether microglia were exposed to 1 or 5 µM LPA (Figures 4–6 and Figures S3–S5, respectively). LPA₅ was shown to play a pathogenic role during focal cerebral ischemia in mice with upregulated (mRNA and protein) expression of LPA₅ in the ischemic core region, whereas LPA₅ antagonism by TCLPA5 treatment significantly attenuated ischemic brain damage [22]. In addition, the authors demonstrated that siRNA-mediated LPA₅ knockdown downregulated gene expression of pro-inflammatory cytokines in LPS-activated BV-2 microglia [22], comparable to our observations in primary LPA-treated LPA₅⁻⁻ microglia (Figure 4). In another model, ischemic brain also exhibited increased ATX activity, LPA concentrations, and LPA receptor expression, with LPA₅ being the most pronounced [62]. These findings were accompanied by disrupted redox balance, BBB dysfunction, and reduced mitochondrial activity. All of these LPA-mediated pathological changes were reversed in response to an ATX and LPA pan-receptor inhibitor (BrP-LPA; [62]). These results are consistent with significantly higher maximal mitochondrial respiration and spare respiratory capacity in LPA₅⁻⁻ microglia compared to wt cells (Figure 5 and Figure S4). A detrimental role of LPA on mitochondrial function is further supported by the fact that heterozygous ATX knockout leads to improved mitochondrial energy homeostasis in brown adipose tissue of mice fed a high-fat, high-sucrose diet [63]. Similarly, a microarray-based approach in brown preadipocytes revealed that ATX-LPA signaling downregulates proteins involved in mitochondrial function and energy metabolism [64].

If LPA compromises mitochondrial function and oxidative phosphorylation, cells might be expected to increase glycolytic flux to meet their energy demand through aerobic glycolysis [65]. Indeed, treatment of wt microglia with LPA led to enhanced lactate secretion (Figure 6A), whereas this response was absent in LPA₅⁻⁻ cells, at least after 2 h, or even reversed after 24 h. The increase in the NADPH/NADP ratio (Figure 6B) is indicative for an increased metabolite flux through the oxidative branch of the pentose phosphate pathway (PPP). The antioxidant function of NADPH for thiorexod activity and GSH recycling is well established. However, it becomes increasingly clear that this hexose monophosphate shunt-derived metabolite can also act as a pro-oxidant during O₂•⁻ production by NADPH.
oxidases or NO generation by iNOS [66]. Our data suggest that LPA in wt microglia causes an increase in the NADPH/NADP ratio that is associated with elevated cellular GSH and NO production (Figure 6C,D). LPA signaling via LPA_5 apparently plays a central role in these pathways, since these metabolic responses are either less pronounced or absent in LPA_5^-/- microglia (Figure 6).

A recent study identified LPA as a modulator of the metabolic landscape in human pluripotent stem cells. The authors reported significantly increased relative amounts of several amino acids and glycolytic, TCA, and PPP intermediates [33], supporting our observations that LPA has the potential to induce metabolic rewiring in microglia ([32] and Figure 6). As for mechanistic pathway analysis, combined LPS/IFNγ treatment of microglia was shown to upregulate G6PDH expression, the first and rate-limiting enzyme of the PPP [67]. The same group showed that increased PPP activity feeds NADPH into NO and ROS synthesis, but also serves as a cofactor of glutathione reductase that converts GSSG back to GSH [67], which is consistent with our data in LPA-treated microglia from wt mice.

In line, upregulated expression and activity of G6PDH in Parkinson’s disease (PD) models was accompanied by excessive NADPH and subsequent ROS production via NOX2 [68]. Knockdown or pharmacological inhibition of G6PDH ameliorated pro-inflammatory microglia polarization, ROS production, and NFκB activation [68]. NADPH-dependent NO synthesis by LPS/IFNγ-activated microglia relies exclusively on efficient glucose flux through the PPP [69]. Microglia use glucose as exclusive energy substrate to generate the superoxide anion radical via NOX2 that transfers electrons to molecular oxygen at the outer and oxidizing NADPH to NADP^+ and H^+ at the inner plasma membrane leaflet [70]. Thus, NADPH (generated via the PPP) can perform two seemingly opposing functions: (i) as an essential antioxidant cofactor of glutathione reductase and thioredoxin, and (ii) as a pro-oxidant trigger of “reductive stress” that leads to the formation of O_2^- and/or NO [66,71], highlighting the close link between redox regulation and immunometabolism [72].

Although our study shows that LPA_5 plays a critical role in neuroinflammation, there are also limitations: in our in vivo experiments, only male mice were used and it is unclear why LPA_5^-/- mice were protected only during the first 24 h during the chronic LPS treatment regimen. For metabolic studies, it is noteworthy that the PPP is not the only source of NADPH, as substantial amounts are also generated via cytosolic and mitochondrial folate-dependent pathways [73] or by cytosolic isocitrate dehydrogenase and the malic enzyme [66]. Of note, NADPH generation during oxidation of methylene tetrahydrofolate to 10-formyl-tetrahydrofolate is also coupled to the cellular GSH/GSSG status [73]. Since we performed only enzymatic assays (and not stable isotope-labeled precursor flux analysis), we are unable to comment on the actual metabolic pathway(s) that generate NADPH. However, considering the strict glucose dependence of microglia for NO production [69], a substantial contribution of the PPP is likely.

Despite these potential shortcomings, our study clearly demonstrates that LPA_5-mediated signaling cascades are centrally involved in the neuroinflammatory response. In this setting, LPA_5^-/- animals and primary cells represent invaluable tools to verify and extend neurological in vivo and in vitro data obtained with pharmacological LPA_5 antagonists.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11071071/s1. Figure S1: Metabolic cage readouts (wt and LPA_5^-/- mice) during the basal 5 d adaptation phase. Figure S2: Metabolic cage readouts (wt and LPA_5^-/- mice) during 4 sequential (24 h apart) LPS injections. Figure S3: LPA_5 regulates LPA-induced secretion of cyto-/chemokines in primary microglia. Figure S4: LPA_5 regulates mitochondrial respiration in primary microglia. Figure S5: LPA_5 regulates extracellular lactate content, NADPH/NADP ratio, glutathione concentration, and NO production in primary microglia.
Author Contributions: Conceptualization, L.J., I.P. and W.S.; methodology, L.J., I.P., E.B., H.R., Z.K. and N.V.; formal analysis, L.J., I.P., E.B. and Z.K., W.F.G., N.V. and D.K.; investigation, all authors; resources, R.R. and J.C.; writing—original draft preparation, L.J., I.P. and W.S.; writing—review and editing, all authors.; supervision, I.P. and W.S.; funding acquisition, W.F.G., D.K., J.C. and W.S. All authors have read and agreed to the published version of the manuscript.

Funding: Open Access Funding by the Austrian Science Fund (FWF). This research was funded by the Austrian Science Fund (DK MOLIN-W1241, SFB F73, DK-MCD W1226, the Medical University of Graz (L.J. within DK-W1241) and BioTechMed-Graz. J.C. received support from the National Institutes of Health (MH051699) and Department of Defense W81XWH-17-1-0455. The funding organizations were not involved in the study design or in the collection, analysis, and interpretation of data.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and the European Directive 2010/63/EU and approved by the Austrian Federal Ministry of Education, Science and Research (BMWF-66.010/0067-V/3b/2018).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on reasonable request from the corresponding author. Reagents and detailed methods of all procedures are provided in the “Materials and Methods” of this manuscript or cited accordingly.

Acknowledgments: We gratefully acknowledge expert technical assistance by Celina Klampfer and Silvia Rainer. The authors thank A. Absenger, M. Singer, and I. Hindler (Medical University of Graz, Austria) for mice care.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ATX Autotaxin
BrP-LPA Bromophosphonate lysophosphatidic acid
CNS Central nervous system
DMSO Dimethyl sulfoxide
GSH Reduced glutathione
iNOS Inducible nitric oxide synthase (NOS2)
LPA Lysophosphatidic acid
LPA1-6 Lysophosphatidic acid receptors 1-6
LPS Lipopolysaccharide
NADPH Nicotinamide adenine dinucleotide phosphate, reduced
NO Nitric oxide
OCR Oxygen consumption rate
PBS Phosphate buffered saline
PPP Pentose phosphate pathway
TLR Toll-like receptor
tMCAO Transient middle cerebral artery occlusion
Wt Wildtype

References
1. Dawson, G. Measuring brain lipids. Biochim. Biophys. Acta 2015, 1851, 1026–1039. [CrossRef] [PubMed]
2. Bozek, K.; Wei, Y.; Yan, Z.; Liu, X.; Xiong, J.; Sugimoto, M.; Tomita, M.; Paabo, S.; Sherwood, C.C.; Hof, P.R.; et al. Organization and evolution of brain lipidome revealed by large-scale analysis of human, chimpanzee, macaque, and mouse tissues. Neuron 2015, 85, 695–702. [CrossRef] [PubMed]
3. Chun, J. Lysophospholipid receptors: Implications for neural signaling. Crit. Rev. Neurobiol. 1999, 13, 151–168. [CrossRef] [PubMed]
4. Ishii, I.; Fukushima, N.; Ye, X.; Chun, J. Lysophospholipid receptors: Signaling and biology. Annu. Rev. Biochem. 2004, 73, 321–354. [CrossRef] [PubMed]
5. Kihara, Y.; Maceyka, M.; Spiegel, S.; Chun, J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br. J. Pharmacol. 2014, 171, 3575–3594. [CrossRef]
6. Yung, Y.C.; Stoddard, N.C.; Mirendil, H.; Chun, J. Lysophosphatidic Acid signaling in the nervous system. *Neuron* **2015**, *85*, 669–682. [CrossRef]

7. Choi, J.W.; Herr, D.R.; Noguchi, K.; Yung, Y.C.; Lee, C.W.; Mutoh, T.; Lin, M.E.; Teo, S.T.; Park, K.E.; Mosley, A.N.; et al. LPA receptors: Subtypes and biological actions. *Annu. Rev. Pharmacol. Toxicol.* **2010**, *50*, 157–186. [CrossRef]

8. Yung, Y.C.; Stoddard, N.C.; Chun, J. LPA receptor signaling: Pharmacology, physiology, and pathophysiology. *J. Lipid. Res.* **2014**, *55*, 1192–1214. [CrossRef]

9. Czirr, E.; Wyss-Coray, T. The immunology of neurodegeneration. *J. Clin. Investig.* **2012**, *122*, 1156–1163. [CrossRef]

10. Labzin, L.I.; Heneka, M.T.; Latz, E. Innate Immunity and Neurodegeneration. *Annu. Rev. Med.* **2018**, *69*, 437–449. [CrossRef]

11. Wolf, S.A.; Boddeke, H.W.; Kettenmann, H. Microglia in Physiology and Disease. *Annu. Rev. Physiol.* **2017**, *79*, 619–643. [CrossRef] [PubMed]

12. Hickman, S.E.; Kingery, N.D.; Ohsumi, T.K.; Borowsky, M.L.; Wang, L.C.; Means, T.K.; El Khoury, J. The microglial sensome revealed by direct RNA sequencing. *Nat. Neurosci.* **2013**, *16*, 1896–1905. [CrossRef] [PubMed]

13. Moller, T.; Contos, J.J.; Musante, D.B.; Chun, J.; Ransom, B.R. Expression and function of lysophosphatidic acid receptors in cultured rodent microglial cells. *J. Biol. Chem.* **2001**, *276*, 25946–25952. [CrossRef]

14. Abels, E.R.; Nieland, L.; Hickman, S.; Broekman, M.L.D.; El Khoury, J.; Maas, S.L.N. Comparative Analysis Identifies Similarities between the Human and Murine Microglial Sensomes. *Int. J. Mol. Sci.* **2021**, *22*, 1495. [CrossRef] [PubMed]

15. Lee, C.W.; Rivera, R.; Gardell, S.; Dubin, A.E.; Chun, J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP. *PLoS. J. Biol. Chem.* **2006**, *281*, 23859–23897. [CrossRef] [PubMed]

16. Pasternack, S.M.; von Kugelgen, I.; Al Aboud, K.; Lee, Y.A.; Ruschendorf, F.; Voss, K.; Hillmer, A.M.; Molderings, G.J.; Franz, T.; Ramirez, A.; et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. *Nat. Genet.* **2008**, *40*, 329–334. [CrossRef]

17. Yanagida, K.; Masago, K.; Nakanishi, H.; Kihara, Y.; Hamano, F.; Tajima, Y.; Taguchi, R.; Shimizu, T.; Ishii, S. Identification and characterization of a novel lysophosphatidic acid receptor, p2Y5/LPA6. *J. Biol. Chem.* **2009**, *284*, 17731–17741. [CrossRef] [PubMed]

18. Plastira, I.; Bernhart, E.; Goeritzer, M.; Reicher, H.; Kumble, V.B.; Kogelnik, N.; Wintersperger, A.; Hammer, A.; Schlager, S.; Jandl, K.; et al. 1-Oleyl-lysophosphatidic acid (LPA) promotes polarization of BV-2 and primary murine microglia towards an M1-like phenotype. *J. Neuroinflamm.* **2015**, *12*, 205. [CrossRef]

19. Kozian, D.H.; von Haeften, E.; Joho, S.; Czechtizky, W.; Anumala, U.R.; Roux, P.; Dudda, A.; Evers, A.; Nazare, M. Modulation of Hexadecyl-LPA-Mediated Activation of Mast Cells and Microglia by a Chemical Probe for LPA5. *ChemBiochem. A Eur. J. Chem. Biol.* **2016**, *17*, 861–865. [CrossRef]

20. Suckau, O.; Gross, I.; Schrotter, S.; Yang, F.; Luo, J.; Wree, A.; Chun, J.; Baska, D.; Baumgart, J.; Kano, K.; et al. LPA1, LPA2, LPA4, and LPA6 receptor expression during mouse brain development. *Dev. Dyn. Off. Publ. Am. Assoc. Anat.* **2019**, *248*, 375–395. [CrossRef]

21. Kwon, J.H.; Gaire, B.P.; Park, S.J.; Shin, D.Y.; Choi, J.W. Identifying lysophosphatidic acid receptor subtype 1 (LPA1) as a novel factor to modulate microglial activation and their TNF-alpha production by activating ERK1/2. *Biochim. Biophys. Acta. Mol. Cell Biol. Lipids* **2018**, *1863*, 1237–1245. [CrossRef] [PubMed]

22. Sakpota, A.; Lee, C.H.; Park, S.J.; Choi, J.W. Lysophosphatidic Acid Receptor 5 Plays a Pathogenic Role in Brain Damage after Focal Cerebral Ischemia by Modulating Neuroinflammatory Responses. *Cells* **2020**, *9*, 1446. [CrossRef] [PubMed]

23. Sakpota, A.; Park, S.J.; Choi, J.W. Inhibition of LPA5 Activity Provides Long-Term Neuroprotection in Mice with Brain Ischemic Stroke. *Biomol. Ther.* **2020**, *28*, 512–518. [CrossRef]

24. Sakpota, A.; Park, S.J.; Choi, J.W. Receptor for Advanced Glycation End Products Is Involved in LPA5-Mediated Brain Damage after a Transient Ischemic Stroke. *Life Sci.* **2021**, *11*, 80. [CrossRef]

25. Lin, M.E.; Rivera, R.R.; Chun, J. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain. *J. Biol. Chem.* **2012**, *287*, 17608–17617. [CrossRef]

26. Callaerts-Vegh, Z.; Leo, S.; Vermaercke, B.; Meert, T.; D’Hooge, R. LPA5 receptor plays a role in pain sensitivity, emotional exploration and reversal learning. *Genes Brain Behav.* **2012**, *11*, 1009–1019. [CrossRef]

27. Murali, N.; Hiyama, H.; Kiso, T.; Sekizawa, T.; Watabiki, T.; Oka, H.; Aoki, T. Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents. *Neuropharmacology* **2017**, *126*, 97–107. [CrossRef]

28. Kozian, D.H.; Evers, A.; Florian, P.; Wonerow, P.; Joho, S.; Nazare, M. Selective non-lipid modulator of LPA5 activity in human platelets. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 5239–5243. [CrossRef]

29. Plastira, I.; Joshi, L.; Bernhart, E.; Schoene, J.; Specker, E.; Nazare, M.; Sattler, W. Small-Molecule Lysophosphatidic Acid Receptor 5 (LPA5) Antagonists: Versatile Pharmacological Tools to Regulate Inflammatory Signaling in BV-2 Microglia Cells. *Front. Cell. Neurosci.* **2019**, *13*, 531. [CrossRef]

30. Awada, R.; Saulnier-Blache, J.S.; Gres, S.; Bourdon, E.; Rondou, P.; Parimisetty, A.; Orihuela, R.; Harry, G.J.; d’Hellencourt, C.L. Autotaxin downregulates LPS-induced microglia activation and pro-inflammatory cytokines production. *J. Cell Biochem.* **2014**, *115*, 2123–2132. [CrossRef]

31. Plastira, I.; Bernhart, E.; Joshi, L.; Koyani, C.N.; Strohmaier, H.; Reicher, H.; Malle, E.; Sattler, W. MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia. *J. Neuroinflamm.* **2020**, *17*, 127. [CrossRef] [PubMed]
32. Joshi, L.; Plastira, I.; Bernhart, E.; Reicher, H.; Koyani, C.N.; Madl, T.; Madreiter-Sokolowski, C.; Koshenov, Z.; Graier, W.F.; Hallstrom, S.; et al. Lysophosphatidic Acid Induces Aerobic Glycolysis, Lipogenesis, and Increased Amino Acid Uptake in BV-2 Microglia. *Int. J. Mol. Sci.* 2021, 22, 1968. [CrossRef]

33. Xu, F.; Deng, C.; Ren, Z.; Sun, L.; Meng, Y.; Liu, W.; Wan, J.; Chen, G. Lysophosphatidic acid shifts metabolic and transcriptional landscapes to induce a distinct cellular state in human pluripotent stem cells. *Cell Rep.* 2021, 37, 110063. [CrossRef] [PubMed]

34. Goeritz, M.; Bernhart, E.; Plastira, I.; Reicher, H.; Leopold, C.; Eichmann, T.O.; Rechberger, G.; Madreiter-Sokolowski, C.T.; Prasch, J.; Eller, P.; et al. Myeloperoxidase and Septic Conditions Disrupt Sphingolipid Homeostasis in Murine Brain Capillaries In Vivo and Immortalized Human Brain Endothelial Cells In Vitro. *Int. J. Mol. Sci.* 2020, 21, 1143. [CrossRef] [PubMed]

35. Chen, Z.; Jalabi, W.; Shippargel, K.B.; Farabaugh, K.T.; Dutta, R.; Yin, X.; Kidd, G.J.; Bergmann, C.C.; Stoliman, S.A.; Trapp, B.D. Lysophosphatidic acid-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. *J. Neurosci.* 2012, 32, 11706–11715. [CrossRef] [PubMed]

36. Joshi, L.; Plastira, I.; Bernhart, E.; Reicher, H.; Triebl, A.; Kofele, H.C.; Sattler, W. Inhibition of Autotaxin and Lysophosphatidic Acid Receptor 5 Attenuates Neuroinflammation in LPS-Activated BV-2 Microglia and a Mouse Endotoxemia Model. *Int. J. Mol. Sci.* 2021, 22, 8519. [CrossRef]

37. Lummis, N.C.; Sánchez-Pavon, P.; Kennedy, G.; Frantz, A.J.; Kihara, Y.; Blaho, V.A.; Chun, J. LPA(1/3) overactivation induces neonatal posthemorrhagic hydrocephalus through ependymal loss and ciliary dysfunction. *Sci. Adv.* 2019, 5, eaax111. [CrossRef]

38. Bernier, L.P.; York, E.M.; MacVicar, B.A. Immunometabolism in the Brain: How Metabolism Shapes Microglial Function. *Trends Neurosci.* 2020, 43, 854–869. [CrossRef]

39. Lynch, M.A. Can the emerging field of immunometabolism provide insights into neuroinflammation? *Prog. Neurobiol.* 2020, 184, 101719. [CrossRef]

40. Hu, Y.; Mai, W.; Chen, L.; Cao, K.; Zhang, B.; Zhang, Z.; Liu, Y.; Lou, H.; Duan, S.; Gao, Z. mTOR-mediated metabolic reprogramming shapes distinct microglia functions in response to lipopolysaccharide and ATP. *Glia* 2020, 68, 1031–1045. [CrossRef]

41. Banks, W.A.; Robinson, S.M. Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. *J. Neuroimmunol.* 2010, 24, 102–109. [CrossRef] [PubMed]

42. Vargas-Caraveo, A.; Sayd, A.; Maus, S.R.; Caso, J.R.; Madrigal, J.L.M.; Garcia-Bueno, B.; Leza, J.C. Lipopolysaccharide enters the rat brain by a lipoprotein-mediated transport mechanism in physiological conditions. *Sci. Rep.* 2017, 7, 13113. [CrossRef] [PubMed]

43. Gao, Q.; Hernandez, M.S. Sepsis-Associated Encephalopathy and Blood-Brain Barrier Dysfunction. *Inflammation* 2021, 44, 2143–2150. [CrossRef] [PubMed]

44. Brown, G.C. The endotoxin hypothesis of neurodegeneration. *J. Neuroinflamm.* 2019, 16, 180. [CrossRef]

45. Liu, W.; Hopkins, A.M.; Hou, J. The development of modulators for lysophosphatidic acid receptors: A comprehensive review. *Bioorg. Med. Chem.* 2021, 117, 105386. [CrossRef]

46. Hauser, A.S.; Attwood, M.M.; Rask-Andersen, M.; Schioth, H.B.; Gloriam, D.E. Trends in GPCR drug discovery: New agents, targets and indications. *Nat. Rev. Drug Discov.* 2016, 15, 829–842. [CrossRef]

47. Banks, W.A. From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery. *Nat. Rev. Drug Discov.* 2016, 15, 275–292. [CrossRef]

48. Mestas, J.; Hughes, C.C. Of mice and not men: Differences between mouse and human immunology. *J. Immunol.* 2004, 172, 2731–2738. [CrossRef]

49. Zhan, X.; Stanova, B.; Jin, L.W.; DeCarli, C.; Phinney, B.; Sharp, F.R. Gram-negative bacterial molecules associate with Alzheimer disease pathology. *Neurology* 2016, 87, 2324–2332. [CrossRef]

50. Alexander, J.J.; Jacob, A.; Cunningham, P.; Hensley, L.; Quigg, R.J. TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1. *Neurochem. Int.* 2008, 52, 447–456. [CrossRef]

51. Nagyoszi, P.; Wilhelm, I.; Farkas, A.E.; Fazakas, C.; Dung, N.T.; Hasko, J.; Krizbai, I.A. Expression and regulation of toll-like receptors in cerebral endothelial cells. *Neurochem. Int.* 2010, 57, 556–564. [CrossRef] [PubMed]

52. Smyth, L.C.D.; Rustenhoven, J.; Park, T.I.; Schweder, P.; Jansson, D.; Heppner, P.A.; O’Carroll, S.J.; Mee, E.W.; Faull, R.L.M.; Curtis, M.; et al. Unique and shared inflammatory profiles of human brain endothelia and pericytes. *J. Neuroinflamm.* 2018, 15, 138. [CrossRef] [PubMed]

53. An, D.; Hao, F.; Zhang, F.; Kong, W.; Chun, J.; Xu, X.; Cui, M.Z. CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation. *J. Biol. Chem.* 2017, 292, 14391–14400. [CrossRef]

54. Zhang, Y.; Chen, K.; Sloan, S.A.; Bennett, M.L.; Scholze, A.R.; O’Keeffe, S.; Phatnani, H.P.; Guarnieri, P.; Caneda, C.; Ruderisch, N.; et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *Neurosurg. Neurosci.* 2014, 34, 11929–11947. [CrossRef] [PubMed]

55. Tang, Y.; Liu, J.; Wang, Y.; Yang, L.; Han, B.; Zhang, Y.; Bai, Y.; Shen, L.; Li, M.; Jiang, T.; et al. PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery. *Autophagy* 2021, 17, 2905–2922. [CrossRef]

56. Kawamoto, Y.; Seo, R.; Murai, N.; Hiyama, H.; Oka, H. Identification of potent lysophosphatidic acid receptor 5 (LPA5) antagonists as potential analgesic agents. *Bioorg. Med. Chem.* 2018, 26, 257–265. [CrossRef]

57. Kittaka, H.; Uchida, K.; Fukuta, N.; Tominaga, M. Lysophosphatidic acid-induced itch is mediated by signalling of LPA(5) receptor, phospholipase D and TRPA1/TRPV1. *J. Physiol.* 2017, 595, 2681–2698. [CrossRef]
58. Dantzer, R.; O’Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9, 46–56. [CrossRef]
59. Biswas, S.K.; Lopez-Collazo, E. Endotoxin tolerance: New mechanisms, molecules and clinical significance. Trends Immunol. 2009, 30, 475–487. [CrossRef]
60. Wendeln, A.C.; Degenhardt, K.; Kaurani, L.; Gertig, M.; Ulas, T.; Jain, G.; Wagner, J.; Hasler, L.M.; Wild, K.; Skodras, A.; et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature 2018, 556, 332–338. [CrossRef]
61. Ulland, T.K.; Song, W.M.; Huang, S.C.; Ulrich, J.D.; Sergushichev, A.; Beatty, W.L.; Loboda, A.A.; Zhou, Y.; Cairns, N.J.; Kambal, A.; et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease. Cell 2017, 170, 649–663.e613. [CrossRef]
62. Bhattarai, S.; Sharma, S.; Ara, H.; Subedi, U.; Sun, G.; Li, C.; Bhuiyan, M.S.; Kevil, C.; Armstrong, W.P.; Minvielle, M.T.; et al. Disrupted Blood-Brain Barrier and Mitochondrial Impairment by Autotaxin-Lysophosphatidic Acid Axis in Postischemic Stroke. J. Am. Heart Assoc. 2021, 10, e021511. [CrossRef]
63. D’Souza, K.; Nziyirera, C.; Cowie, A.M.; Varghese, G.P.; Trivedi, P.; Eichmann, T.O.; Biswas, D.; Touaibia, M.; Morris, A.J.; Aidinis, V.; et al. Autotaxin-LPA signaling contributes to obesity-induced insulin resistance in muscle and impairs mitochondrial metabolism. J. Lipid Res. 2018, 59, 1805–1817. [CrossRef] [PubMed]
64. Federico, L.; Ren, H.; Mueller, P.A.; Wu, T.; Liu, S.; Popovic, J.; Blalock, E.M.; Sunkara, M.; Ovaa, H.; Albers, H.M.; et al. Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol. Endocrinol. 2012, 26, 786–797. [CrossRef]
65. Lunt, S.Y.; Vander Heiden, M.G. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 2011, 27, 441–464. [CrossRef] [PubMed]
66. Xiao, W.; Wang, R.S.; Handy, D.E.; Loscalzo, J. NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism. Antioxid. Redox Signal. 2018, 28, 251–272. [CrossRef]
67. Gimeno-Bayon, J.; Lopez-Lopez, A.; Rodriguez, M.J.; Mahy, N. Glucose pathways adaptation supports acquisition of activated microglia phenotype. J. Neurosci. Res. 2014, 92, 723–731. [CrossRef]
68. Tu, D.; Gao, Y.; Yang, R.; Guan, T.; Hong, J.S.; Gao, H.M. The pentose phosphate pathway regulates chronic neuroinflammation and dopaminergic neurodegeneration. J. Neuroinflamm. 2019, 16, 255. [CrossRef]
69. Castillo, E.; Mocanu, E.; Uruk, G.; Swanson, R.A. Glucose availability limits microglial nitric oxide production. J. Neurochem. 2021, 159, 1008–1015. [CrossRef]
70. Ghosh, S.; Castillo, E.; Frias, E.S.; Swanson, R.A. Bioenergetic regulation of microglia. Glia 2018, 66, 1200–1212. [CrossRef]
71. Xiao, W.; Loscalzo, J. Metabolic Responses to Reductive Stress. Antioxid. Redox Signal. 2020, 32, 1330–1347. [CrossRef]
72. Muri, J.; Kopf, M. Redox regulation of immunometabolism. Nat. Rev. Immunol. 2021, 21, 363–381. [CrossRef] [PubMed]
73. Fan, J.; Ye, J.; Kamphorst, J.J.; Shlomi, T.; Thompson, C.B.; Rabinowitz, J.D. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 2014, 510, 298–302. [CrossRef]